Evidence map›Paper›PMID 36962332›Full record

ArticlePLOS global public health2022

Differential diagnosis of COVID-19 and influenza.

Farrokh Alemi, Jee Vang, Janusz Wojtusiak, Elina Guralnik, Rachele Peterson, Amira Roess, Praduman Jain

Open access · goldFull text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Order of Occurrence of COVID-19 Symptoms.Quality management in health care
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Farrokh AlemiDepartment of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, VA, United States of America.ORCID https://orcid.org/0000-0002-7402-9063
Jee VangDepartment of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, VA, United States of America.
Janusz WojtusiakDepartment of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, VA, United States of America.
Elina GuralnikDepartment of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, VA, United States of America.ORCID https://orcid.org/0000-0002-7624-0620
Rachele PetersonVibrent Health, Inc., Fairfax, VA, United States of America.ORCID https://orcid.org/0000-0002-0266-0235
Amira RoessDepartment of Global and Community Health, College of Health and Human Services, George Mason University, Fairfax, VA, United States of America.ORCID https://orcid.org/0000-0003-2321-1575
Praduman JainVibrent Health, Inc., Fairfax, VA, United States of America.
George Mason University · US

Funding

DIGITAL HEALTH SOLUTIONS FOR COVID-19: COVID COMMUNITY ACTION AND RESEARCH ENGAGEMENT (COVID-CARE)75N91020C00038 · NCI · VIGNET, INC. · PI JAIN, PRADUMAN · 2020 to 2021
$4.0M
NCI NIH HHS 75N91020C00038
6 · The paper itself

Abstract

This study uses two existing data sources to examine how patients' symptoms can be used to differentiate COVID-19 from other respiratory diseases. One dataset consisted of 839,288 laboratory-confirmed, symptomatic, COVID-19 positive cases reported to the Centers for Disease Control and Prevention (CDC) from March 1, 2019, to September 30, 2020. The second dataset provided the controls and included 1,814 laboratory-confirmed influenza positive, symptomatic cases, and 812 cases with symptomatic influenza-like-illnesses. The controls were reported to the Influenza Research Database of the National Institute of Allergy and Infectious Diseases (NIAID) between January 1, 2000, and December 30, 2018. Data were analyzed using case-control study design. The comparisons were done using 45 scenarios, with each scenario making different assumptions regarding prevalence of COVID-19 (2%, 4%, and 6%), influenza (0.01%, 3%, 6%, 9%, 12%) and influenza-like-illnesses (1%, 3.5% and 7%). For each scenario, a logistic regression model was used to predict COVID-19 from 2 demographic variables (age, gender) and 10 symptoms (cough, fever, chills, diarrhea, nausea and vomiting, shortness of breath, runny nose, sore throat, myalgia, and headache). The 5-fold cross-validated Area under the Receiver Operating Curves (AROC) was used to report the accuracy of these regression models. The value of various symptoms in differentiating COVID-19 from influenza depended on a variety of factors, including (1) prevalence of pathogens that cause COVID-19, influenza, and influenza-like-illness; (2) age of the patient, and (3) presence of other symptoms. The model that relied on 5-way combination of symptoms and demographic variables, age and gender, had a cross-validated AROC of 90%, suggesting that it could accurately differentiate influenza from COVID-19. This model, however, is too complex to be used in clinical practice without relying on computer-based decision aid. Study results encourage development of web-based, stand-alone, artificial Intelligence model that can interview patients and help clinicians make quarantine and triage decisions.

Identifiers

PMID36962332
PMCPMC10021438
OpenAlexW4286203392

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.